KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.85

Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy.

Maria Riccarda Del Bene, Icro Meattini, Giuseppe Pilato, Carlotta Becherini, Francesca Martella, Viola Salvestrini, Livia Marrazzo, Calogero Saieva, Iacopo Olivotto, Giuseppe Barletta, Lorenzo Livi

Echocardiography 42(9) e70291

PMID40965835
PMCIDPMC12445402
DOI10.1111/echo.70291
发表日期2025-09-18
入排依据:Although the record describes a substudy of a definitive randomized oncology trial in humans, the reported outcomes are cardiac toxicity endpoints (RV function, CTRCD), not the required survival or efficacy outcomes for Kaplan-Meier digitization.
已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:森林图/亚组分析图。
摘要

摘要

PURPOSE: To evaluate the effects of cardioprotective therapy (CPT) with neurohormonal inhibitors on cancer therapeutics-related cardiac dysfunction (CTRCD) in breast cancer patients, focusing on right ventricular (RV) function. METHODS: This is a secondary analysis of SAFE study, a randomized, phase 3, double-blind, placebo-controlled, four-arm trial, in which the effects of short-term CPT (bisoprolol, ramipril, or both) compared to placebo (P-arm) on subclinical CTRCD were evaluated in 222 women without cardiac risk factors who received intensive anthracycline-based chemotherapy (median isoequivalent doxorubicin dose 288 mg/m2). Among them, 35% received trastuzumab, 98% taxanes, 22% underwent neoadjuvant therapy, 78% adjuvant therapy, and 56% had postoperative radiotherapy. CPT started with chemotherapy and continued for 1 year, or until the completion of trastuzumab therapy. All the patients underwent cardiac surveillance at baseline and 3, 6, 12, and 24 months. Left ventricular CTRCD was assessed following the 2022 ESC guidelines. RV function was evaluated according to established recommendations. RV CTRCD was defined as a greater than 10% reduction in RV fractional area change (FAC). RESULTS: At 24 months, LV CTRCD was observed in 42.9% of P-arm and 3.1% of the CPT arms (p < 0.001). Compared to the CPT arms, there was a significant reduction in RV FAC (-10.5%), S'-wave velocity (-12.2%), and tricuspid annular plane systolic excursion (-9.6%) in the P-arm. Additionally, the RV diameter increased by 7% in the P-arm. RV CTRCD was found in 49.2% of the P-arm and 22% of the CPT arms (p < 0.001). CONCLUSION: Short-term neurohormonal cardioprotection was effective in reducing RV CTRCD.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 Representative two‐dimensional right‐oriented four‐chamber images to measure (from left to right) the right ventricular diameter, diastolic and systolic areas used to calculate the fractional area change (FAC), and the right atrium volume (RAV) (top panel). On the bottom panel, the continuous‐wave Doppler tricuspid flow velocity from which the tricuspid systolic pressure gradient is calculated, the tricuspid annular plane systolic excursion (TAPSE), and the systolic velocity of tricuspid annulus (S’) by tissue Doppler imaging.
非 KM Figure
FIGURE 2FIGURE 2 Trajectories of the percent changes over time of the right ventricular parameters. Color‐coded symbols identify the study arm as indicated at the bottom. Abbreviations: FAC: fractional area change; PASP: pulmonary artery systolic pressure; RAV: right atrium volume; RV: right ventricular; S'RV: pulsed tissue Doppler systolic wave velocity; TAPSE: tricuspid annular plane systolic excursion.
非 KM Figure
FIGURE 3FIGURE 3 Pie chart of the distribution of cancer therapy–related cardiac dysfunction (CTRCD).
非 KM Figure
FIGURE 4FIGURE 4 Histograms of the distribution and incidence of cancer therapy–related cardiac dysfunction (CTRCD) according to the treatment with trastuzumab or not. Bar color‐coding is reported under the graph. Abbreviations: CTRCD: cancer therapy–related cardiac dysfunction; LV: left ventricular; RV: right ventricular.
非 KM Figure
FIGURE 5FIGURE 5 Forest plot of the determinants of right ventricular cardiotoxicity by univariate logistic analysis. In red, the drug arms versus the Placebo. Abbreviations: ad: adjuvant; AIS: aromatase inhibitors; aLHRH: luteinizing hormone‐releasing hormone agonist; BMI: body mass index; CHT: chemotherapy intent; HER2: human epidermal growth factor receptor 2; HR: hormonal receptor; HT: adjuvant endocrine therapy; neoad: neoadjuvant; RNI: regional nodal irradiation; RT: radiotherapy.
非 KM Figure